#23 - Tom Dayspring, M.D., FACP, FNLA – Part IV of V: Statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
The Peter Attia Drive
00:00
Do You Know if It Matters in a Clinical Trial?
i remember amjen kinnd of got hammered when the trial came out, because people thought, eh, that wasn't enough of an improvement. But if you look at it from a scientific standpoint, that you could take that patient population and achieve that outcome is one of the most remarkable things in cardio vascular medicine. And to your point, it doesn't even speak to the patients that i have on pc s canine inhibitors.
Transcript
Play full episode
